Calidi Biotherapeutics, Inc. (CLDI) Dividend History

Calidi Biotherapeutics, Inc. (CLDI) is a biotechnology company focused on developing advanced cell-based immunotherapies for cancer and infectious diseases. The company leverages proprietary platform technologies, including its tumor-targeting and immune-activating cell systems, to create innovative treatments aimed at improving patient outcomes.

Dividend History

Calidi Biotherapeutics, Inc. currently does not pay dividends

Company News

  • Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

    Calidi Biotherapeutics, a clinical-stage biotechnology company, announced the closing of a $4.25 million public offering of 5,000,000 shares of common stock at $0.85 per share. The company is developing targeted antitumor virotherapies.

    GlobeNewswire Inc.
  • Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

    Calidi Biotherapeutics, a clinical-stage biotechnology company, has priced a public offering of 4,437,869 shares of its common stock at $1.69 per share, raising approximately $7.5 million. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials.

    Benzinga
  • Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

    Calidi Biotherapeutics reported its Q2 2024 financial results, including a net loss of $5.8 million. The company made several key developments, including launching a new subsidiary, Nova Cell, with a $2 million investment, and receiving a new U.S. patent for its SuperNova technology platform.

    GlobeNewswire Inc.
  • Calidi Biotherapeutics announces 1-for-10 reverse stock split - Investing.com

    Calidi Biotherapeutics, a biotechnology company, announced a 1-for-10 reverse stock split to enhance shareholder value. The move aims to increase the per-share trading price and potentially satisfy listing requirements.

    Investing.com
  • S&P 500 Edges Lower; PacBio Shares Plunge

    U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.02% to 37,741.96 while the NASDAQ fell 0.20% to 15,853.39. The S&P 500 also fell, dropping, 0.28% to 5,047.76. Check This Out: Alphabet, Toll Brothers And 2 Other Stocks Insiders Are Selling   Leading and Lagging Sectors   Information technology shares rose by 0.4% on Tuesday. In trading on Tuesday, real estate shares fell by 1.8%.   Top Headline   Industrial production in the U.S. increased by 0.4% from the prior month in March versus a revised 0.4% rise in the prior month.   Equities Trading UP   Jaguar Health, Inc. (NASDAQ: JAGX) shares shot up 52% to $0.1809 after the company signed an exclusive 5-year in-license agreement with Venture Life Group for Gelclair. Shares of WiSA Technologies, Inc. (NASDAQ: WISA) got a boost, surging 261% to $6.32 after the company announced a 5-year WiSA E licensing agreement with an HDTV/PTV brand. Palisade Bio, Inc. (NASDAQ: PALI) shares were also up, gaining 37% to $5.67 after the company announced the completion of analysis evaluating ex-vivo bioactivation of PALI-2108.   Equities Trading DOWN   Barnes & Noble Education, ...

    Benzinga
    Featured Companies: BNED JAGX PACB PALI
Dividend data last updated 06/07/2025 20:48:06 UTC